FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer

(MedPage Today) -- The FDA granted accelerated approval for the antibody-drug conjugate (ADC) mirvetuximab soravtansine (Elahere) for folate receptor α (FRα)-positive platinum-resistant ovarian cancer. The action makes mirvetuximab the...
Source: MedPage Today Public Health - Category: American Health Source Type: news